Physician profile
Ian Marshall
NPI 1396760450
$51,385.41
in general payments reported to CMS, 2019-2025
15 companies · $32K in 2025
The $32K reported for 2025 was more than what 95% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $94.39 · 2021: $4,730 · 2022: $72.10 · 2023: $905 · 2024: $14K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Travel and Lodging: $3,876 · Food and Beverage: $1,895 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,600.00 |
| Travel and Lodging | $3,875.73 |
| Food and Beverage | $1,895.32 |
| Education | $117.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $45,703.08 | 2023-2025 | Crenessity |
| Eton Pharmaceuticals, INC. | $4,730.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $224.26 | 2024 | |
| Tolmar, INC. | $175.84 | 2024 | |
| Alexion Pharmaceuticals, INC. | $115.15 | 2024 | Strensiq |
| Tandem Diabetes Care, INC. | $114.33 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Biomarin Pharmaceutical INC. | $107.89 | 2024 | Voxzogo 1.2mg |
| Medtronic Minimed, INC. | $94.39 | 2020 | |
| Medtronic, INC. | $51.34 | 2022 | |
| Janssen Biotech, INC. | $28.40 | 2025 | Erleada |
| Baxter Healthcare | $20.76 | 2022 | |
| Sumitomo Pharma America, INC. | $19.60 | 2025 | Orgovyx |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.